The DURIPANC study, a collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands, is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion.

Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:

• No significant toxicity, an encouraging safety profile for a post-chemo setting.
• Around 21% of patients have progression-free survival (PFS) of over 6 months (3/14), with an additional 21% not yet progressed.
• The majority (64%) of eligible patients had an overall survival of over 6 months, which is better than expected in this setting.

AIM has developed an intellectual property plan specific to pancreatic cancer that includes a recently issued U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to Aug. 9, 2039.

AIM Price Action: AIM ImmunoTech shares were up 36.79% at $11.49 at the time of publication on Monday, according to Benzinga Pro data.

Read Next:

• Palantir’s Next Stop Is $200, Says Jim Cramer As PLTR Glides ‘Like A Knife Through Butter’

Photo: jittawit21/Shutterstock